• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IIQ
Click for more information
2.06% 49.5¢

INOVIQ LTD - Charts / Financials

Market Cap $45.54M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and... INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.31pm 09/05/2024 (20 minute delay) ?
Day
Open 48.0¢   Day High 51.5¢   Day Low 47.5¢
Daily Volume 66843
Bids   Sellers
Number Price Volume   Number Price Volume
1 50.0¢ 2500   1 51.0¢ 8000

Directors & Senior Management

Dr. Leearne Maree Hinch Chief Executive Officer
Mr. Mark Edwards Chief Financial Officer, Company Secretary
Prof. Greg Rice Chief Scientific Officer
Mr. David John Williams Non-Executive Chairman of the Board
Mr. Geoffrey Cumming Non-Executive Director
Mr. Robert Maxwell Johnston Non-Executive Director
Mr. Philip J. Powell Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
49.5¢ 		Change
0.010(2.06%) 		Mkt cap ! $45.54M
Open High Low Value Volume
48.0¢ 51.5¢ 47.5¢ $33.20K 66.84K

Buyers (Bids)

No. Vol. Price($)
1 2500 50.0¢
 

Sellers (Offers)

Price($) Vol. No.
51.0¢ 8000 1
View Market Depth
Last trade - 15.43pm 09/05/2024 (20 minute delay) ?
Last
50.5¢ 		  Change
0.010 ( 4.12 %)
Open High Low Volume
49.0¢ 50.5¢ 49.0¢ 9065
Last updated 15.31pm 09/05/2024 ?

Top Stories

Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan

Prominence Energy has seen shares rise 33% on news of uranium grading up to 5,269ppm from early sampling work in Kazakhstan.
UNITH's digital humans expand into Amazon; Facebook AI-powered 'Digital Human' chatbot developer UNITH has announced its in-house tech can now harmonise with that used by Facebook and Amazon.
CBA profits fall 3% in March quarter but funding portfolio is flourishing Commonwealth Bank has reported a 3 percent fall in profits for the March quarter of 2024, compared to the previous quarter.
Raiden opens door to private Mallina in win-win Arrow Gold divestment Raiden Resources has announced its execution of a farm-in deal on-site Raiden's non-core asset, the Arrow gold project.
Recce breathes better on positive lung infection drug pilot test results Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327, which aims to treat lung infections.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.